Protagonist Announces Positive One-Year Phase 3 Data for ICOTYDE in Moderate-to-Severe Plaque Psoriasis.

Protagonist Therapeutics announced new one-year Phase 3 results for ICOTYDE (icotrokinra), a once-daily oral peptide for moderate-to-severe plaque psoriasis, at the 2026 American Academy of Dermatology Annual Meeting. Data from the ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies support the potential of ICOTYDE as a differentiated oral therapy, demonstrating lasting skin clearance and a favorable safety profile. The findings highlight the power of Protagonist's peptide discovery platform and its ability to create highly differentiated oral medicines.